# US 2022/0033464 A1 · Methods and compositons for modulations of immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033464 A1
- Document ID: US20220033464A1
- Status: Published application
- Kind: A1
- Application number: 17/270,403
- Filed: 2019-08-23
- Published: 2022-02-03
- Earliest claimed: 2018-08-24
- Assignees: La Jolla Institute for Immunology; University of Southampton
- Applicants: La Jolla Institute for Immunology; University of Southampton
- Inventors: Pandurangan VIJAYANAND; Ferhat AY; Divya SINGH; Anusha Preethi GANESAN; Bharat PANWAR; Christian OTTENSMEIER
- Web page: https://patentgrep.com/patent/US20220033464A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/521: {Chemokines}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70514: {CD4}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/7158: {for chemokines}
- C12N 9/6467: {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}
- C12Y 304/21079: Granzyme B (3.4.21.79)
- G01N 33/5091: {for testing the pathological state of an organism}
- A61K 2239/57: Skin; melanoma
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are isolated follicular helper T cell (TFH) and engineered follicular helper T cell (TFH) and methods of isolating or engineering such cells. Further disclosed herein are methods of using such cells for treating diseases, such as cancer.

## Claims

### Claim 1

An engineered T-follicular helper (Tfh)-like tumor-infiltrating cell engineered to modulate expression of the surface markers CD4, CXCL13 and CXCR5 or one or more proteins selected from MAF, SH2D1A (SAP), PDCD1, BTLA, CD200, and BCL6.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the cell is engineered to express the surface markers CD4 and CXCL13 and lack the surface marker CXCR5.

### Claim 3 (depends on 1)

The cell of claim 1 wherein the cell is further engineered to express GZMB.

### Claim 4 (depends on 1)

The cell of claim 1, wherein the cell is a Tfh-like tumor-infiltrating cell that activates a CD8+ CTL response.

### Claim 5 (depends on 4)

The cell of claim 4, wherein the CD8+ CTL response is activated in a tumor or tumor microenvironment.

### Claim 6 (depends on 1)

The cell of claim 1, wherein the cell is a Tfh-like tumor-infiltrating cell that activates a CD8+ TRM response.

### Claim 7 (depends on 6)

The cell of claim 6, wherein the CD8+ TRM response is activated in a tumor or tumor microenvironment.

### Claim at position 8

-9. (canceled)

### Claim 10

An isolated T-follicular helper (Tfh)-like tumor-infiltrating cell expressing the surface markers CD4 and CXCL13 and lacking the surface marker CXCR5.

### Claim 11 (depends on 10)

The cell of claim 10, wherein the cell is a cytotoxic Tfh-like tumor-infiltrating cell expressing GZMB.

### Claim 12 (depends on 1)

The cell of claim 1, wherein the cell is engineered to increase expression and/or function of one or more of: TNFRSF18, TNFRSF4, IFNG, Granzyme B and/or IL21 in the cell.

### Claim 13 (depends on 1)

The cell of claim 1, wherein the cell is engineered to expresses an antigen binding domain that binds at least one tumor antigen.

### Claim 14 (depends on 13)

The cell of claim 13, wherein the tumor antigen comprises any one of: a CD19, a disialoganglioside-GD2, a c-mesenchymal-epithelial transition (c-Met), a mesothelin, a ROR1, an EGFRvIII, an ephrin type-A receptor 2 (EphA2), an interleukin (IL)-13r alpha 2, an EGFR V111, a PSMA, an EpCAM, a GD3, a fucosyl GM1, a PSCA, a PLAC1, a sarcoma breakpoint, a Wilms Tumor 1 antigen or a combination thereof.

### Claim 15 (depends on 1)

The cell of claim 1, wherein the cell is engineered to express or expresses an antigen binding domain that binds at least one antigen.

### Claim 16 (depends on 15)

The cell of claim 15, wherein the antigen is selected from a neo-antigen, tumor-associated antigen, viral antigen, bacterial antigen, and parasitic antigen.

### Claim 17 (depends on 1)

The cell of claim 1, wherein the cell further comprises a suicide gene.

### Claim 18 (depends on 1)

The cell of claim 1, wherein the cell further comprises a chimeric antigen receptor (CAR).

### Claim 19 (depends on 18)

The cell of claim 18, wherein the chimeric antigen receptor (CAR) comprises: (a) an antigen binding domain; (b) a hinge domain; (c) a transmembrane domain; (d) and an intracellular domain and optionally a CD3 zeta signaling domain.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The cell of claim 19, wherein the antigen binding domain of the CAR binds a tumor antigen.

### Claim at position 21

-55. (canceled)

### Claim 56

A method of determining whether a subject will respond to a treatment for cancer comprising measuring the amount of one or more of: CD4+CXCL13+CXCR5− Tfh-like tumor-infiltrating cell, and/or CD4+CXCL13+CXCR5′GZMB+ cytotoxic Tfh-like tumor-infiltrating cell in a sample isolated from the subject, wherein higher amounts of the cells indicates that the subject is likely to respond to the treatment and lower amounts of the cells indicates that the subject is not likely to respond to the treatment.

### Claim at position 23

-62. (canceled)

### Claim 63 (depends on 1)

A method of treating cancer in a subject comprising administering to the subject an effective amount of the cell of claim 1.

### Claim at position 25

-70. (canceled)
